Contact Us
Drug Search Results
More Filters [+]

IDRX-42

Alternative Names: IDRX-42, IDRX 42, IDRX42
Latest Update: 2025-01-31
Latest Update Note: Clinical Trial Update

Product Description

IDRX-42, an orally administered small molecule tyrosine kinase inhibitor, is a drug candidate from IDRx for the treatment of Metastatic and/or Unresectable Gastrointestinal Stromal Tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05489237?term=IDRX-42&draw=2&rank=1)

Mechanisms of Action: TK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: IDRX, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for IDRX-42

Countries in Clinic: Belgium, China, France, Germany, Italy, Korea, Netherlands, South Korea, Spain, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Digestive System Cancer|Gastrointestinal Cancer|Gastrointestinal Stromal Tumors|Intestinal Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
jRCT2051240255

P1

Not yet recruiting

Gastrointestinal Stromal Tumors

2027-10-31

Study ID: StrateGIST 1

P1

Recruiting

Gastrointestinal Cancer|Digestive System Cancer|Intestinal Diseases|Gastrointestinal Stromal Tumors

2026-04-24

Recent News Events

Date

Type

Title

01/22/2025

News Article

 Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

01/13/2025

News Article

 GSK Enters Agreement to Acquire IDRx, Inc.

11/14/2024

News Article

 IDRx Announces Updated Phase 1 Data from Ongoing Phase 1/1b StrateGIST 1 Trial of IDRX-42 in Advanced Gastrointestinal Stromal Tumors (GIST) at CTOS 2024

08/07/2024

News Article

 IDRx Announces $120 Million Series B Financing to Advance Potential Best-in-class New Treatment for Gastrointestinal Stromal Tumor (GIST)

03/01/2024

PubMed

 KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.

08/01/2023

PubMed

 Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line-Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST).

02/23/2023

PubMed

 Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions